ILMN stock forecast, quote, news & analysis
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications... Show more
Why Illumina (ILMN) Stock Is Up +18.6% in the Last 30 Days
Key Takeaways
- Illumina (ILMN) shares rose roughly 18.6% over the 30 days through late September 2026, advancing from about $227.69 to $270.00.
- The move was fueled by the company's addition to the S&P 500 index, a series of analyst upgrades, and sustained clinical sequencing demand.
- Over the trailing three months, the stock gained approximately 52%, extending a broad multi-month uptrend.
- Second-quarter 2026 results beat Wall Street expectations, prompting management to raise full-year revenue and earnings guidance.
- Investors continue to weigh headwinds including China restrictions, cost inflation, and elevated insider selling.
Illumina (ILMN) Company Overview and Market Position
Illumina, Inc. is a San Diego-based genomics company that develops sequencing and array-based technologies used to analyze genetic variation and function. Its instruments, consumables, and software serve applications across oncology, reproductive health, agriculture, and other emerging fields. Customers include genomic research centers, academic institutions, hospitals, government laboratories, and pharmaceutical, biotechnology, and diagnostics companies.
Following the 2024 spin-off of GRAIL, Illumina has concentrated on three pillars: its core sequencing business, an expanding multiomics portfolio, and broader services, data, and software capabilities. The acquisition of proteomics company SomaLogic in January 2026 broadened its reach into protein measurement. Its flagship NovaSeq X platform remains the central driver of high-throughput sequencing demand, and the company holds a leading position in clinical and research sequencing markets.
Illumina (ILMN) Stock Price Performance: Last 30 Days vs. Quarter
Illumina shares closed at $270.00 in late September 2026, compared with $227.69 thirty days earlier, a gain of approximately 18.6%. The rally accelerated in mid-September, when the stock broke above the $240 level amid heavy trading volume tied to index-driven buying.
The move sits within a much larger advance. Over the trailing quarter, the stock rose from roughly $177 in late June to $270, an increase of about 52%. That longer trajectory reflects a steady climb through the summer, punctuated by a strong post-earnings reaction and a late-quarter surge as passive funds adjusted positions around the company's S&P 500 inclusion.
What Drove ILMN Stock Price in the Last 30 Days
Several verified catalysts underpinned the recent gain. The most mechanical was index inclusion: Illumina joined the S&P 500 effective September 21, 2026, migrating up from the S&P MidCap 400. The move forced index-tracking funds to buy shares, adding demand that coincided with the stock's sharpest gains of the period. The company was also added to the S&P 500 Equal Weighted Index and removed from the Russell Small Cap Value Index.
Analyst actions reinforced sentiment. Argus raised its price target to $235 from $180, UBS upgraded the stock to Buy from Neutral with a $260 target, and Stifel reaffirmed a Buy rating. These revisions followed better-than-expected second-quarter results reported in late July, when revenue rose 9.5% year over year to $1.16 billion and adjusted EPS of $1.31 beat the $1.23 consensus estimate.
Fundamental momentum also mattered. More than 95 NovaSeq X systems were placed in the second quarter, and roughly 78% of clinical sequencing volume now runs on the platform, supporting the recurring consumables revenue that underpins the company's growth. The strength of clinical demand helped offset softer research funding and persistent China headwinds.
What Drove ILMN Stock Performance Over the Last Quarter
The broader three-month advance reflects a re-rating of the business rather than a single event. Strong first-half execution, including consecutive earnings beats, built confidence in Illumina's clinical growth trajectory. Management raised full-year 2026 revenue guidance to $4.60 billion to $4.64 billion and adjusted EPS guidance to $5.30 to $5.40, up from prior ranges, signaling durable demand for sequencing-intensive clinical applications.
At the same time, the stock's climb has moved it ahead of the average analyst price target, and notable insider selling has emerged as a counterweight. Director Keith Meister disposed of more than $255 million in shares between early August and mid-September. China remains restricted following the company's placement on the Unreliable Entity List, and freight, memory, and component costs continue to pressure margins. These factors have not reversed the uptrend but remain central to the valuation debate.
Trending AI Robots
For traders seeking a data-driven edge across equities like Illumina, Tickeron's Trending AI Robots page offers a curated view of its most relevant automated trading systems. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, yet only the top-performing and most pertinent bots are highlighted in this section. Each robot differs in trading strategy, holding timeframe, and performance metrics, giving investors the ability to compare approaches rather than rely on a single model. The curated selection is designed to help users identify automated strategies aligned with current market conditions. Explore the Trending AI Robots page to see which systems are currently drawing attention.
ILMN Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape Illumina's stock in the near term. The durability of clinical consumables growth and the pace of NovaSeq X conversions toward management's 80% to 85% year-end target will be closely watched. Third-quarter results and any updates to full-year guidance will test whether the raised outlook remains on track.
Macro and regulatory risks also warrant attention, including the status of China restrictions, tariffs, and memory and freight costs. Competitive pressure in sequencing and ongoing integration of the SomaLogic business could influence margins. Finally, the balance between index-driven demand and continued insider selling may affect near-term supply dynamics. These developments provide context for investors rather than a basis for any specific prediction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ILMN in -2.51% downward trend, declining for three consecutive days on October 13, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ILMN declined for three days, in 254 of 330 cases, the price declined further within the following month. The odds of a continued downward trend are 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ILMN moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 18 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 69 cases where ILMN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ILMN as a result. In 67 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for ILMN turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 38 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
ILMN broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a +10.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in 199 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 180 of 214 cases where ILMN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.472) is normal, around the industry mean (72.578). P/E Ratio (50.728) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (3.355) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (7.843) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of integrated systems for the analysis of genetic variation and function
Industry MedicalSpecialties